Head-to-head evidence
Ertugliflozin vs Rongliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Ertugliflozin · Steglatro
Marketed by Merck & Co. and partners
NCT01986881 · Phase 3 · completed
This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.
Next expected readout: January 2028 · NCT07621380 (registry estimate)
Rongliflozin
Developed by Sunshine Lake Pharma
NCT05427682 · Phase 1 · completed
A non-randomized, open-label, parallel-group pharmacokinetic study of rongliflozin in 32 participants with normal or impaired liver function. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ertugliflozin's landscape · Rongliflozin's landscape